Cleared Traditional

K770787 - RELAXATION COURSE MOLEL 1000

K770787 is the FDA 510(k) clearance for RELAXATION COURSE MOLEL 1000 by Cybernetic Medical, Inc.. It is a Class 2 Neurology device (product code HCC) cleared through the Traditional 510(k) pathway after a 46-day FDA review.

K770787 · Cybernetic Medical, Inc. · Neurology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Jun 1977
Decision
46d
Days
Class 2
Risk

K770787 is an FDA 510(k) clearance for the RELAXATION COURSE MOLEL 1000. Classified as Device, Biofeedback (product code HCC), Class II - Special Controls.

Submitted by Cybernetic Medical, Inc. (Mchenry, US). The FDA issued a Cleared decision on June 17, 1977 after a review of 46 days - a notably fast clearance cycle.

This device falls under the Neurology FDA review panel, regulated under 21 CFR 882.5050 - the FDA neurology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

View all Cybernetic Medical, Inc. devices

Submission Details

510(k) Number K770787 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received May 02, 1977
Decision Date June 17, 1977
Days to Decision 46 days
Submission Type Traditional
Review Panel Neurology (NE)
Summary -
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
102d faster than avg
Panel avg: 148d · This submission: 46d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

Device Classification

Product Code HCC Device, Biofeedback
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 882.5050
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Neurology devices follow this clearance model.